



Chemicals & Petrochemicals | Small Cap
Aristo Bio-Tech & Lifescience Ltd demonstrates a mixed financial performance. The company shows strong solvency and growth, driven by effective management of debt and impressive increases in revenue, operating profit, and EPS. Profitability metrics are also robust, supported by healthy gross profit and operating margins. However, liquidity is a concern, with ratios indicating potential difficulties in meeting short-term obligations. While efficiency ratios are generally average, there are notable strengths in asset turnover. The company's financial ratios reveal some weaknesses in earnings per share and book value per share, despite adequate capital expenditure. Overall, Aristo Bio-Tech showcases solid financial health, but needs to improve its liquidity position and financial metrics to ensure long-term stability and growth.
Aristo Bio-Tech & Lifescience Ltd demonstrates a mixed financial performance. The company shows strong solvency and growth, driven by effective management of debt and impressive increases in revenue, operating profit, and EPS. Profitability metrics are also robust, supported by healthy gross profit and operating margins. However, liquidity is a concern, with ratios indicating potential difficulties in meeting short-term obligations. While efficiency ratios are generally average, there are notable strengths in asset turnover. The company's financial ratios reveal some weaknesses in earnings per share and book value per share, despite adequate capital expenditure. Overall, Aristo Bio-Tech showcases solid financial health, but needs to improve its liquidity position and financial metrics to ensure long-term stability and growth.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
9.76
Industry Median
15.03
Small Cap Median
14.06
P/E RATIO
9.76
P/B RATIO
1.57
Industry Median
2.03
Small Cap Median
2.03
P/S RATIO
N/A
Industry Median
1.38
Small Cap Median
1.38
Others
PEG RATIO
0.00
EV/EBITDA RATIO
0.00
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹103 as on Sep 1, 2026.
The company demonstrates strong growth across various metrics. The revenue growth rate is impressive, indicating successful expansion of sales. The operating profit growth rate is also robust, reflecting improved operational efficiency. Earnings per share (EPS) growth is significant, showing enhanced profitability for shareholders. The asset growth rate is healthy, reflecting strategic investments and expansion. The net income growth rate is also substantial, indicating improved overall profitability. These factors collectively suggest that the company is experiencing strong and sustainable growth.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -0.6 | 31.33 | 12.39 | 29.8 | 14.47 |
| Operating Profit Growth Rate | 25 | 80 | -11.11 | 12.5 | 77.78 |
| Earnings Per Share (EPS) Growth | -0.93 | 144.39 | 9.56 | 4.01 | 77.01 |
| Asset Growth Rate | -4.94 | 29.87 | 27 | 11.02 | 9.93 |
| Net Income Growth Rate | 0 | 300 | 0 | 0 | 75 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Aristo Bio-Tech & Lifescience Ltd | 7.93 | 9.76 | Neutral | 16.00 | 10.55 | 7.00 |
| 2 | Crop Life Science Ltd | 6.87 | 19.24 | Neutral | 18.00 | 4.08 | 6.00 |
| 3 | AMBEY | N/A | N/A | N/A | N/A | N/A | N/A |
| 4 | AIMCOPEST | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
No Stock News Available at This Moment.
Aristo Bio-Tech & Lifescience Ltd is an Indian agrochemical company specializing in manufacturing, formulating, and marketing a diverse range of crop protection products. Its portfolio includes insecticides, fungicides, herbicides, and plant growth regulators, catering to the agricultural sector's needs for enhancing crop yield and quality in India and internationally.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Aristo Bio-Tech & Lifescience Ltd's P/E ratio (TTM) is 9.76, compared to the industry median of 15.03 and large cap median of 14.06.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Aristo Bio-Tech & Lifescience Ltd's P/B ratio is 1.57, compared to the industry median of 2.03 and large cap median of 2.03.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Aristo Bio-Tech & Lifescience Ltd's P/S ratio is 2.10, compared to the industry median of 1.38 and large cap median of 1.38.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Aristo Bio-Tech & Lifescience Ltd's PEG ratio is 0.95.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Aristo Bio-Tech & Lifescience Ltd's EV/EBITDA ratio is 11.80.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Aristo Bio-Tech & Lifescience Ltd's ROE is 15.56%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Aristo Bio-Tech & Lifescience Ltd's ROA is 10.32%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Aristo Bio-Tech & Lifescience Ltd's ROCE is 20%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Aristo Bio-Tech & Lifescience Ltd's operating margin is 4.40%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Aristo Bio-Tech & Lifescience Ltd's net margin is 1.92%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Aristo Bio-Tech & Lifescience Ltd's current ratio is 1.27.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Aristo Bio-Tech & Lifescience Ltd's debt-to-equity ratio is 0.16.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Aristo Bio-Tech & Lifescience Ltd's interest coverage ratio is 3.50.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Aristo Bio-Tech & Lifescience Ltd's DPS is ₹0.63.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Aristo Bio-Tech & Lifescience Ltd's EPS is 77.01.
(Source line: "Ratios as of 22 Nov 2026, based on last traded price of ₹103. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2005 (as Aristo Bio-Tech & Lifescience Private Limited)
Headquarters: Ahmedabad, Gujarat
Core Offerings: Insecticides, Fungicides, Herbicides, Plant Growth Regulators, Adjuvants
Stock Listing: NSE (ARISTO), BSE ({bse})
Promoter: Mr. Rajendrakumar P. Patel & family
2005: Incorporated as Aristo Bio-Tech & Lifescience Private Limited.
Early Years: Focused on manufacturing and trading agrochemical formulations.
22 March 2023: Converted to a Public Limited Company.
2023: Successfully launched an SME IPO to list on NSE Emerge, expanding operations and market reach.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Agrochemicals (Formulations & Technicals) | 100% | N/A (single segment) |
Insecticides: Offers a wide range of insecticides to protect crops from various insect pests, ensuring better crop health and yield.
Fungicides: Provides effective solutions for controlling fungal diseases in crops, safeguarding against significant agricultural losses.
Herbicides: Develops and markets herbicides to manage weeds efficiently, reducing competition for nutrients and improving crop productivity.
Plant Growth Regulators & Adjuvants: Supplies products that enhance plant growth, development, and overall physiological processes, along with adjuvants to improve the efficacy of agrochemical applications.
Mr. Rajendrakumar P. Patel (Chairman & Managing Director) - He is the founder and promoter of the company, with extensive experience in the agrochemical industry, steering the company's strategic direction and growth.
No major subsidiaries reported.
No major recent corporate actions on record since its SME IPO.
The Aristo Bio-Tech & Lifescience Ltd share price today is ₹103 on NSE (ARISTO), as of 22 Nov 2026.
As of 22 Nov 2026, Aristo Bio-Tech & Lifescience Ltd share price is ₹103, with previous close ₹103. Today's range is ₹103 to ₹103. The 52-week range is ₹74.30 to ₹128.50.
As of today, Aristo Bio-Tech & Lifescience Ltd's market cap is ₹0 crore (Small Cap).
Aristo Bio-Tech & Lifescience Ltd's current P/E ratio is 9.76, compared to the CHEMICALS & PETROCHEMICALS sector average of 27.50.
Aristo Bio-Tech & Lifescience Ltd's current P/B ratio is 1.57.
Aristo Bio-Tech & Lifescience Ltd's current dividend yield is 0.61%. Last dividend of ₹0.00 per share was declared on N/A.
Aristo Bio-Tech & Lifescience Ltd's EPS (TTM) is ₹77.01.
Aristo Bio-Tech & Lifescience Ltd is an Indian agrochemical company specializing in manufacturing, formulating, and marketing a diverse range of crop protection products. Its portfolio includes insecticides, fungicides, herbicides, and plant growth regulators, catering to the agricultural sector's needs for enhancing crop yield and quality in India and internationally.
Aristo Bio-Tech & Lifescience Ltd is promoted by Mr. Rajendrakumar P. Patel & family, holding 73.42% as of 22 Nov 2026.
Aristo Bio-Tech & Lifescience Ltd is listed on NSE (ARISTO) and BSE ({bse}). Its next quarterly results are expected on Q1 FY25 results expected around August 2024.